Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RGEN 
Repligen Corporation (RGEN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: RGEN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
19 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $179.22
1 Year Target Price $179.22
| 10 | Strong Buy |
| 4 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -30.55% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.72B USD | Price to earnings Ratio - | 1Y Target Price 179.22 |
Price to earnings Ratio - | 1Y Target Price 179.22 | ||
Volume (30-day avg) 19 | Beta 1.07 | 52 Weeks Range 102.97 - 182.52 | Updated Date 09/17/2025 |
52 Weeks Range 102.97 - 182.52 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.25 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -2.05% | Operating Margin (TTM) 5.28% |
Management Effectiveness
Return on Assets (TTM) 1.13% | Return on Equity (TTM) -0.68% |
Valuation
Trailing PE - | Forward PE 58.14 | Enterprise Value 6714058755 | Price to Sales(TTM) 9.97 |
Enterprise Value 6714058755 | Price to Sales(TTM) 9.97 | ||
Enterprise Value to Revenue 9.96 | Enterprise Value to EBITDA 67.47 | Shares Outstanding 56257618 | Shares Floating 52661068 |
Shares Outstanding 56257618 | Shares Floating 52661068 | ||
Percent Insiders 6.38 | Percent Institutions 99.2 |
Upturn AI SWOT
Repligen Corporation
Company Overview
History and Background
Repligen Corporation was founded in 1981. Initially focused on recombinant protein A, it evolved to provide bioprocessing technologies, acquiring several companies to expand its portfolio. Key milestones include the development of innovative filtration and chromatography products.
Core Business Areas
- Filtration: Repligen offers filtration products, including tangential flow filtration (TFF) systems, used for separation and purification in biomanufacturing.
- Chromatography: This segment includes chromatography columns and resins essential for purifying biopharmaceuticals.
- Process Analytics: Provides instruments and software for real-time monitoring and control of bioprocessing.
- Protein A Ligands: Supply of recombinant Protein A ligands used in affinity chromatography for antibody purification.
- Cell Culture: Products for cell culture including growth factors.
Leadership and Structure
Tony J. Hunt is the CEO. The company has a typical corporate structure with departments for R&D, manufacturing, sales, and marketing. A board of directors oversees the company's strategy.
Top Products and Market Share
Key Offerings
- OPUS Columns: Pre-packed chromatography columns used for downstream purification of biopharmaceuticals. Dominant player in pre-packed column market with estimated 30% market share. Competitors include Cytiva and Sartorius.
- KrosFlo TFF Systems: Tangential flow filtration systems for cell separation, clarification, and concentration. Repligen has strong market presence in TFF segment. Competitors include Sartorius and Pall Corporation.
- Protein A Ligands: Critical component in downstream processes. Repligen is a major provider. Competitors include Purolite and GenScript.
Market Dynamics
Industry Overview
The bioprocessing market is growing rapidly, driven by increasing demand for biopharmaceuticals. This includes monoclonal antibodies, vaccines, gene and cell therapies. The industry is characterized by continuous innovation and increasing automation.
Positioning
Repligen is a leading provider of bioprocessing technologies, well-positioned to benefit from the growth in the biopharmaceutical market. Its competitive advantages include a broad product portfolio, strong customer relationships, and innovative technology.
Total Addressable Market (TAM)
The total addressable market for bioprocessing technologies is estimated to be in tens of billions of dollars, and Repligen is targeting significant portions of this market with its diverse product offerings.
Upturn SWOT Analysis
Strengths
- Broad product portfolio
- Strong customer relationships
- Innovative technology
- Experienced management team
- Global reach
Weaknesses
- Reliance on acquisitions for growth
- High valuation
- Potential supply chain vulnerabilities
- Dependence on key suppliers
Opportunities
- Expanding into new geographic markets
- Developing new products and services
- Acquiring complementary businesses
- Partnerships with biopharmaceutical companies
- Growing demand for single-use technologies
Threats
- Increased competition
- Price pressure
- Technological obsolescence
- Economic downturn
- Changes in regulatory requirements
Competitors and Market Share
Key Competitors
- DHR
- SMCI
- SYK
Competitive Landscape
Repligen's competitive advantages include its broad product portfolio and strong customer relationships. However, it faces competition from larger, more diversified companies.
Major Acquisitions
Avitide
- Year: 2019
- Acquisition Price (USD millions): 150
- Strategic Rationale: Expanded Repligen's ligand discovery and development capabilities.
Growth Trajectory and Initiatives
Historical Growth: Repligen has experienced significant growth in recent years, driven by organic growth and acquisitions. Revenue has increased substantially.
Future Projections: Analysts project continued growth for Repligen, driven by the increasing demand for bioprocessing technologies. Projected growth data is unavailable
Recent Initiatives: Recent strategic initiatives include acquisitions of bioprocessing companies and investments in R&D.
Summary
Repligen is a strong company with a leading position in the bioprocessing market, fueled by innovative products and strategic acquisitions. Its broad product portfolio and strong customer relationships are significant advantages. However, high valuation and reliance on acquisitions are potential risks. Continued innovation and market expansion will be crucial for sustaining growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on available information and is not financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Repligen Corporation
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 1990-03-26 | President, CEO & Director Mr. Olivier Loeillot | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 1778 | Website https://www.repligen.com |
Full time employees 1778 | Website https://www.repligen.com | ||
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.